Safety and Immunogenicity of a ChAd155-Vectored Respiratory Syncytial Virus Vaccine in Infants 6–7 Months of age: A Phase 1/2 Randomized TrialXavier Sáez‐Llorens, Nicolas Vanhoutte, Jerzy Brzostek et al.|The Journal of Infectious Diseases|2023Cited by 13
Efficacy, Immunogenicity, and Safety of an Investigational Maternal Respiratory Syncytial Virus Prefusion F Protein–Based VaccinePeyman Banooni, Marta Picciolato, Bernard Gonik et al.|Clinical Infectious Diseases|2025Cited by 7
Landscape of Invasive Fusariosis in Pediatric Cancer Patients: Results of a Multicenter Observational Study From Latin AmericaFabianne Carlesse, Arnaldo Lopes Colombo, Adriana Maria Paixão de Sousa da Silva et al.|Open Forum Infectious Diseases|2024Cited by 5
Incidence of Respiratory Syncytial Virus–Associated Lower Respiratory Tract Illness in Infants in Low- and Middle-Income Regions During the Coronavirus Disease 2019 PandemicSamantha Fry, Gaël Dos Santos, Kulkanya Chokephaibulkit et al.|Open Forum Infectious Diseases|2023Cited by 3